Bausch Health Companies Inc. (BHC) reported $11.11B of revenue for the twelve months ended Sep 30, 2026. That is up 10.8% from the year before. Revenue for fiscal 2025 was $10.27B.

No. Bausch Health Companies Inc. reported a net loss of $841.00M for the twelve months ended Sep 30, 2026.

How much cash and debt does BHC have?

Bausch Health Companies Inc. reported $2.48B in cash and cash equivalents and $20.64B of debt on its most recent balance sheet in SEC filings.

How fast is BHC revenue growing?

Bausch Health Companies Inc.'s revenue changed +6.7% in fiscal 2025, to $10.27B. Its compound annual growth rate was +5.0% over 5 years and -0.2% over 10 years.

What is BHC free cash flow?

Bausch Health Companies Inc. generated $1.86B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $2.21B less capital expenditures.

What is BHC earnings per share?

Diluted earnings per share were -$2.29 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did BHC last report financial results?

The latest statements here come from Bausch Health Companies Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.

Financials · BHC

Bausch Health Companies Inc. (BHC) financials

For the twelve months ended Sep 30, 2026, Bausch Health Companies Inc. reported $11.11B of revenue and -$841.00M of net income.

Revenue, TTM: $11.11B
Revenue growth, YoY: +10.8%
Net income, TTM: -$841.00M
Net margin: -7.6%
Free cash flow, TTM: $1.86B
EPS, diluted, TTM: -$2.29
Cash: $2.48B
Total debt: $20.64B
P/S: 0.28
Market cap: $3.14B

Annual revenue$10.27B

FY2016FY2025

Annual net income$157.00M

FY2016FY2025

Annual free cash flow$1.00B

FY2016FY2025

BHC revenue and earnings growth

BHC revenueQ3 2026$2.94B

Quarter YoY: +9.7%
QoQ: +3.1%
FY YoY: +6.7%
5Y CAGR: +5.0%
10Y CAGR: -0.2%

BHC revenue was $2.94B in fiscal Q3 2026 (ended Sep 30, 2026), up 9.7% from a year earlier and up 3.1% from the prior quarter. For the full fiscal 2025 it was $10.27B, up 6.7% from fiscal 2024. Compound annual growth was +5.0% over 5 years and -0.2% over 10 years. It rose in 5 of the last 10 fiscal years.

BHC net incomeQ3 2026$436.00M

Quarter YoY: +143.6%
QoQ: +69.0%

BHC net income was $436.00M in fiscal Q3 2026 (ended Sep 30, 2026), up 143.6% from a year earlier and up 69.0% from the prior quarter. For the full fiscal 2025 it was $157.00M, compared with -$46.00M in fiscal 2024.

BHC EPSQ3 2026$1.15

Quarter YoY: +139.6%
QoQ: +69.1%

BHC diluted EPS was $1.15 in fiscal Q3 2026 (ended Sep 30, 2026), up 139.6% from a year earlier and up 69.1% from the prior quarter. For the full fiscal 2025 it was $0.42, compared with -$0.13 in fiscal 2024.

BHC free cash flowQ3 2026$748.00M

Quarter YoY: +138.2%
QoQ: +26.1%
FY YoY: -20.4%
5Y CAGR: +4.4%
10Y CAGR: -6.8%

BHC free cash flow was $748.00M in fiscal Q3 2026 (ended Sep 30, 2026), up 138.2% from a year earlier and up 26.1% from the prior quarter. For the full fiscal 2025 it was $1.00B, down 20.4% from fiscal 2024. Compound annual growth was +4.4% over 5 years and -6.8% over 10 years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$10.27B	$9.63B	$8.76B	$8.12B	$8.43B	$8.03B	$8.60B	$8.38B	$8.72B	$9.67B
Cost of revenue	-	-	-	-	-	-	-	-	$2.51B	$2.57B
Gross profit	-	-	-	-	-	-	-	-	$6.22B	$7.10B
Research and development	$629.00M	$616.00M	$604.00M	$529.00M	$465.00M	$452.00M	$471.00M	$413.00M	$361.00M	$421.00M
Selling, general and admin	$3.44B	$3.30B	$2.92B	$2.63B	$2.62B	$2.37B	$2.55B	$2.47B	$2.58B	$2.81B
Operating income	$1.81B	$1.55B	$963.00M	$454.00M	$450.00M	$676.00M	-$203.00M	-$2.38B	$102.00M	-$566.00M
Pre-tax income	$367.00M	$167.00M	-$390.00M	-$129.00M	-$1.02B	-$934.00M	-$1.84B	-$4.15B	-$1.74B	-$2.44B
Income tax	$247.00M	$239.00M	$221.00M	$83.00M	-$87.00M	-$375.00M	-$54.00M	-$10.00M	-$4.14B	-$27.00M
Net income	$157.00M	-$46.00M	-$592.00M	-$225.00M	-$948.00M	-$560.00M	-$1.79B	-$4.15B	$2.40B	-$2.41B
EPS, basic	$0.42	-$0.13	-$1.62	-$0.62	-$2.64	-$1.58	-$5.08	-$11.81	$6.86	-$6.94
EPS, diluted	$0.42	-$0.13	-$1.62	-$0.62	-$2.64	-$1.58	-$5.08	-$11.81	$6.83	-$6.94
Diluted shares	375.0M	368.0M	364.9M	362.0M	358.9M	355.0M	352.1M	351.3M	351.8M	347.3M

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$1.31B	$1.20B	$947.00M	$591.00M	$2.12B	$1.82B	$3.24B	$721.00M	$797.00M	$542.00M
Receivables	$2.35B	$2.14B	$2.00B	$1.79B	$1.77B	$1.58B	$1.84B	$1.86B	$2.13B	$2.52B
Inventory	$1.63B	$1.59B	$1.54B	$1.09B	$993.00M	$1.09B	$1.11B	$934.00M	$1.05B	$1.06B
Current assets	$6.16B	$5.77B	$5.60B	$4.25B	$5.61B	$5.34B	$6.97B	$4.21B	$4.75B	$5.08B
Goodwill	$11.27B	$11.09B	$11.18B	$11.55B	$12.46B	$13.04B	$13.13B	$13.14B	$15.59B	$15.79B
Total assets	$26.37B	$26.52B	$27.35B	$25.69B	$29.20B	$31.20B	$33.86B	$32.49B	$37.50B	$43.53B
Current liabilities	$4.18B	$6.75B	$4.30B	$3.94B	$5.20B	$4.91B	$6.25B	$3.84B	$4.27B	$3.61B
Short-term debt	$225.00M	$2.67B	$450.00M	$432.00M	$0	$0	$1.23B	$228.00M	$209.00M	$1.00M
Long-term debt	$20.59B	$18.94B	$21.94B	$20.33B	$22.65B	$23.93B	$24.66B	$24.08B	$25.23B	$29.84B
Total debt	$20.82B	$21.62B	$22.39B	$20.77B	$22.65B	$23.93B	$25.89B	$24.30B	$25.44B	$29.85B
Total liabilities	$25.99B	$26.84B	$27.43B	$25.43B	$29.24B	$30.59B	$32.73B	$29.68B	$31.55B	$40.27B
Shareholders' equity	-$554.00M	-$322.00M	-$82.00M	$260.00M	-$34.00M	$605.00M	$1.14B	$2.81B	$5.94B	$3.26B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$1.40B	$1.60B	$1.03B	-$728.00M	$1.43B	$1.11B	$1.50B	$1.50B	$2.29B	$2.09B
Capital expenditures	$397.00M	$337.00M	$215.00M	$218.00M	$269.00M	$302.00M	$270.00M	$157.00M	$171.00M	$235.00M
Free cash flow	$1.00B	$1.26B	$817.00M	-$946.00M	$1.16B	$809.00M	$1.23B	$1.34B	$2.12B	$1.85B
Investing cash flow	-$595.00M	-$454.00M	-$2.15B	-$303.00M	$409.00M	-$261.00M	-$419.00M	-$196.00M	$2.89B	-$125.00M
Financing cash flow	-$742.00M	-$868.00M	$1.48B	-$474.00M	-$1.51B	-$2.29B	$1.44B	-$1.35B	-$4.96B	-$1.96B
Share repurchases	-	-	-	-	-	-	-	-	$0	$0
Stock-based compensation	$216.00M	$150.00M	$132.00M	$126.00M	$128.00M	$105.00M	$102.00M	$87.00M	$87.00M	$165.00M
Depreciation and amortization	$1.21B	$1.27B	$1.26B	$1.39B	$1.55B	$1.82B	$2.08B	$2.82B	$2.86B	$2.87B

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	6.7%	9.9%	7.8%	-3.7%	5.1%	-6.7%	2.6%	-3.9%	-9.8%	-7.4%
Gross margin	-	-	-	-	-	-	-	-	71.3%	73.4%
Operating margin	17.7%	16.1%	11.0%	5.6%	5.3%	8.4%	-2.4%	-28.4%	1.2%	-5.9%
Net margin	1.5%	-0.5%	-6.8%	-2.8%	-11.2%	-7.0%	-20.8%	-49.5%	27.6%	-24.9%
Free cash flow margin	9.8%	13.1%	9.3%	-11.6%	13.7%	10.1%	14.3%	16.0%	24.3%	19.1%
Return on equity	-	-	-	-86.5%	-	-92.6%	-157.4%	-147.4%	40.4%	-73.9%
Return on assets	0.6%	-0.2%	-2.2%	-0.9%	-3.2%	-1.8%	-5.3%	-12.8%	6.4%	-5.5%
Current ratio	1.47	0.86	1.30	1.08	1.08	1.09	1.12	1.10	1.11	1.41
Debt to equity	-	-	-	79.87	-	39.55	22.79	8.63	4.28	9.16

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$2.94B	$2.85B	$2.52B	$2.80B	$2.68B	$2.53B	$2.26B	$2.56B	$2.51B	$2.40B	$2.15B	$2.41B
Research and development	$141.00M	$173.00M	$163.00M	$161.00M	$166.00M	$159.00M	$143.00M	$163.00M	$146.00M	$156.00M	$151.00M	$152.00M
Selling, general and admin	$834.00M	$907.00M	$861.00M	$882.00M	$795.00M	$894.00M	$867.00M	$820.00M	$850.00M	$832.00M	$794.00M	$766.00M
Operating income	$983.00M	$740.00M	-$950.00M	$474.00M	$619.00M	$444.00M	$276.00M	$558.00M	$318.00M	$389.00M	$281.00M	$362.00M
Pre-tax income	$597.00M	$348.00M	-$1.35B	$56.00M	$218.00M	$140.00M	-$47.00M	$209.00M	-$21.00M	$48.00M	-$69.00M	-$7.00M
Income tax	$151.00M	$88.00M	$77.00M	$159.00M	$37.00M	$12.00M	$39.00M	$111.00M	$71.00M	$49.00M	$8.00M	$40.00M
Net income	$436.00M	$258.00M	-$1.42B	-$112.00M	$179.00M	$148.00M	-$58.00M	$93.00M	-$85.00M	$10.00M	-$64.00M	-$39.00M
EPS, basic	$1.16	$0.69	-$3.82	-$0.30	$0.48	$0.40	-$0.16	$0.24	-$0.23	$0.03	-$0.17	-$0.11
EPS, diluted	$1.15	$0.68	-$3.82	-$0.30	$0.48	$0.40	-$0.16	$0.24	-$0.23	$0.03	-$0.17	-$0.11
Diluted shares	380.7M	378.1M	372.8M	-	375.5M	373.1M	369.6M	-	368.4M	370.2M	366.8M	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$2.48B	$1.82B	$1.30B	$1.31B	$1.31B	$1.73B	$1.13B	$1.20B	$719.00M	$595.00M	$733.00M	$947.00M
Receivables	$2.53B	$2.26B	$2.19B	$2.35B	$2.42B	$2.21B	$2.07B	$2.14B	$2.09B	$2.10B	$2.05B	$2.00B
Inventory	$1.59B	$1.60B	$1.60B	$1.63B	$1.60B	$1.66B	$1.61B	$1.59B	$1.66B	$1.61B	$1.64B	$1.54B
Current assets	$7.41B	$6.52B	$5.98B	$6.16B	$6.25B	$6.51B	$5.73B	$5.77B	$5.35B	$5.21B	$5.40B	$5.60B
Goodwill	$9.77B	$9.79B	$9.81B	$11.27B	$11.29B	$11.30B	$11.15B	$11.09B	$11.17B	$11.13B	$11.16B	$11.18B
Total assets	$25.48B	$24.79B	$24.50B	$26.37B	$26.82B	$27.27B	$26.42B	$26.52B	$26.54B	$26.50B	$26.91B	$27.35B
Current liabilities	$4.75B	$4.54B	$4.53B	$4.18B	$4.79B	$4.97B	$4.26B	$6.75B	$4.51B	$4.37B	$4.41B	$4.30B
Short-term debt	$866.00M	$866.00M	$889.00M	$225.00M	$579.00M	$879.00M	$282.00M	$2.67B	$453.00M	$452.00M	$538.00M	$450.00M
Long-term debt	$19.77B	$19.88B	$19.88B	$20.59B	$20.46B	$20.86B	$21.23B	$18.94B	$21.05B	$21.21B	$21.54B	$21.94B
Total debt	$20.64B	$20.74B	$20.76B	$20.82B	$21.04B	$21.74B	$21.51B	$21.62B	$21.51B	$21.66B	$22.07B	$22.39B
Total liabilities	$25.82B	$25.60B	$25.58B	$25.99B	$26.47B	$27.12B	$26.66B	$26.84B	$26.78B	$26.72B	$27.09B	$27.43B
Shareholders' equity	-$1.33B	-$802.00M	-$1.08B	-$554.00M	$356.00M	$147.00M	-$240.00M	-$322.00M	-$242.00M	-$227.00M	-$174.00M	-$82.00M

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$814.00M	$670.00M	$230.00M	$495.00M	$405.00M	$289.00M	$211.00M	$601.00M	$405.00M	$380.00M	$211.00M	$390.00M
Capital expenditures	$66.00M	$77.00M	$109.00M	$92.00M	$91.00M	$99.00M	$115.00M	$106.00M	$71.00M	$78.00M	$82.00M	$98.00M
Free cash flow	$748.00M	$593.00M	$121.00M	$403.00M	$314.00M	$190.00M	$96.00M	$495.00M	$334.00M	$302.00M	$129.00M	$292.00M
Investing cash flow	-$83.00M	-$93.00M	-$139.00M	-$282.00M	-$83.00M	-$100.00M	-$130.00M	-$200.00M	-$102.00M	-$79.00M	-$73.00M	-$148.00M
Financing cash flow	-$80.00M	-$49.00M	-$100.00M	-$235.00M	-$719.00M	$358.00M	-$146.00M	$85.00M	-$189.00M	-$424.00M	-$340.00M	-$79.00M
Stock-based compensation	$52.00M	$54.00M	$52.00M	$84.00M	$43.00M	$46.00M	$43.00M	$43.00M	$38.00M	$36.00M	$33.00M	$29.00M
Depreciation and amortization	$284.00M	$281.00M	$295.00M	$290.00M	$306.00M	$307.00M	$305.00M	$307.00M	$322.00M	$318.00M	$320.00M	$329.00M

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	9.7%	12.7%	11.7%	9.3%	6.8%	5.3%	4.9%	6.3%	12.2%	10.9%	10.8%	9.8%
Net income growth, YoY	143.6%	74.3%	-	-	-	1380.0%	-	-	-	-61.5%	-	-
EPS growth, YoY	139.6%	70.0%	-	-	-	1233.3%	-	-	-	-57.1%	-	-
Operating margin	33.4%	25.9%	-37.6%	17.0%	23.1%	17.5%	12.2%	21.8%	12.7%	16.2%	13.1%	15.0%
Net margin	14.8%	9.0%	-56.4%	-4.0%	6.7%	5.8%	-2.6%	3.6%	-3.4%	0.4%	-3.0%	-1.6%
Free cash flow margin	25.4%	20.8%	4.8%	14.4%	11.7%	7.5%	4.2%	19.3%	13.3%	12.6%	6.0%	12.1%
Current ratio	1.56	1.44	1.32	1.47	1.30	1.31	1.35	0.86	1.19	1.19	1.22	1.30
Debt to equity	-	-	-	-	59.11	147.88	-	-	-	-	-	-

Source: XBRL data Bausch Health Companies Inc. files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

BHC peers

Company	Revenue	Growth	Net income	Net margin	Market cap
BHC	$11.11B	+10.8%	-$841.00M	-7.6%	$3.14B
LLYEli Lilly and Company	$86.46B	+45.5%	$27.58B	31.9%	$1.33T
JNJJohnson & Johnson	$99.33B	+7.8%	$16.09B	16.2%	$679.13B
ABBVAbbVie Inc.	$66.01B	+10.7%	$10.34B	15.7%	$518.44B
MRKMerck & Company Inc.	$67.38B	+4.9%	$2.45B	3.6%	$366.73B
NVSNovartis AG	$54.53B	+8.4%	$13.98B	25.6%	$312.35B
AZNAstraZeneca PLC	$58.74B	+8.6%	$10.22B	17.4%	$293.69B
ABTAbbott Laboratories	$48.23B	+10.0%	$4.70B	9.7%	$191.40B
NVONovo Nordisk A/S	DKK 309.06B	+6.4%	DKK 102.43B	33.1%	$183.23B

BHC FAQ

8 questions

What is BHC revenue?
Bausch Health Companies Inc. (BHC) reported $11.11B of revenue for the twelve months ended Sep 30, 2026. That is up 10.8% from the year before. Revenue for fiscal 2025 was $10.27B.
Is BHC profitable?
No. Bausch Health Companies Inc. reported a net loss of $841.00M for the twelve months ended Sep 30, 2026.
How much cash and debt does BHC have?
Bausch Health Companies Inc. reported $2.48B in cash and cash equivalents and $20.64B of debt on its most recent balance sheet in SEC filings.
How fast is BHC revenue growing?
Bausch Health Companies Inc.'s revenue changed +6.7% in fiscal 2025, to $10.27B. Its compound annual growth rate was +5.0% over 5 years and -0.2% over 10 years.
What is BHC free cash flow?
Bausch Health Companies Inc. generated $1.86B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $2.21B less capital expenditures.
What is BHC earnings per share?
Diluted earnings per share were -$2.29 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did BHC last report financial results?
The latest statements here come from Bausch Health Companies Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.
Where does this BHC financial data come from?
Quantisnow builds these statements from the structured XBRL data Bausch Health Companies Inc. files with the SEC. It is provided for information only and is not investment advice.